Antiphosphatidylethanolamine antibodies and the antiphospholipid syndrome

Lupus

Volumn 18, Issue 10, 2009, Pages 920-923

  Sanmarco, Marielle ^a   Boffa, M C ^b  

^a HÔPITAL DE LA CONCEPTION   (France)

^b HÔPITAL JEAN VERDIER   (France)

Author keywords

Antiphosphatidylethanolamine antibodies; Antiphospholipid antibodies; Antiphospholipid syndrome; Recurrent foetal losses; Thrombosis

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLETHANOLAMINE ANTIBODY; UNCLASSIFIED DRUG;

ADULT BOVINE SERUM; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FETAL CALF SERUM; FETUS WASTAGE; HUMAN; IMMUNOASSAY; MICROTITER PLATE ASSAY; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; REVIEW; SERUM; STANDARDIZATION; THROMBOSIS;

ABORTION, HABITUAL; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PHOSPHATIDYLETHANOLAMINES; THROMBOSIS;

EID: 68949166322     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309106920     Document Type: Review

References (24)

1. McIntyre JA Wagenknecht DR. Anti-phosphatidylethanolamine (aPE) antibodies: A survey. J Autoimmun 2000; 15: 185-193.
2. Smirnov MD Ford DA Esmon CT Esmon NL. The effect of membrane composition on the hemostatic balance. Biochemistry 1999; 38: 3591-3598.
3. Norstrøm EA Steen M Tran S Dahlbäck B. Importance of protein S and phospholipid for activated protein C-mediated cleavages in factor Va. J Biol Chem 2003; 278: 24904-24911.
4. Baumgärtner P Geiger M Zieseniss S et al. Phosphatidylethanolamine critically supports internalization of cell-penetrating protein C inhibitor. J Cell Biol 2007; 179: 793-804.
5. Tsuda T Yoshimura H Hamasaki N. Effect of phosphatidylcholine, phosphatidylethanolamine and lysophosphatidylcholine on the activated factor X-prothrombin system. Blood Coagul Fibrinolysis 2006; 17: 465-469.
6. Rauch J Tannenbaum M Tannenbaum H et al. Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. J Biol Chem 1986; 261: 9672-9677.
7. Janoff AS Rauch J. The structural specificity of anti-phospholipid antibodies in autoimmune disease. Chem Phys Lipids 1986; 40: 315-332.
8. Rauch J Tannenbaum M Neville C Fortin PR. Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanolamine in the presence of prothrombin. Thromb Haemost 1998; 80: 936-941.
9. Drouvalakis KA Buchanan RR. Phospholipid specificity of autoimmune and drug induced lupus anticoagulants; association of phosphatidylethanolamine reactivity with thrombosis in autoimmune disease. J Rheumatol 1998; 25: 290-295.
10. Drouvalakis KA Neeson PJ Buchanan RR. Detection of anti-phosphatidylethanolamine antibodies using flow cytometry. Cytometry 1999; 36: 46-51.
11. Berard M Boffa MC. Influence of the phosphatidylethanolamine (PE) and bovine serum origins on anti-PE antibody detection by ELISA. Thromb Res 1997; 85: 439-442.
12. Drouvalakis KA Buchanan RR. Microtitre plate and assay buffer alter detection of antiphosphatidylethanolamine antibodies in lupus anticoagulant positive plasma. Thromb Res 1999; 94: 205-212.
13. Sugi T McIntyre JA. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 1995; 86: 3083-3089.
14. Sugi T McIntyre JA. Certain autoantibodies to phosphatidylethanolamine (aPE) recognize factor XI and prekallikrein independently or in addition to the kininogens. J Autoimmun 2001; 17: 207-214.
15. Vlachoyiannopoulos PG Beigbeder G Dueymes M et al. Antibodies to phosphatidylethanolamine in antiphospholipid syndrome and systemic lupus erythematosus: Their correlation with anticardiolipin antibodies and beta 2 glycoprotein-I plasma levels. Autoimmunity 1993; 16: 245-249.
16. Sanmarco M Alessi MC Harle JR et al. Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses. Thromb Haemost 2001; 85: 800-805.
17. Staub HL Harris EN Khamashta MA Savidge G Chahade WH Hughes GR. Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis. Ann Rheum Dis 1989; 48: 166-169.
18. Berard M Chantome R Marcelli A Boffa MC. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases. J Rheumatol 1996; 23: 1369-1374.
19. Sanmarco M Gayet S Alessi MC et al. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost 2007; 97: 949-954.
20. Sugi T Katsunuma J Izumi SI McIntyre JA Makino T. Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses. Fertil Steril 1999; 71: 1060-1065.
21. Gris JC Quéré I Sanmarco M et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early fætal loss. Thromb Haemost 2000; 84: 228-236.
22. Sugi T Matsubayashi H Inomo A Dan L Makino TJ. Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss. Obstet Gynaecol Res 2004; 30: 326-332.
23. Sanmarco M Bardin N Camoin L et al. Antigenic profile, prevalence, and clinical significance of antiphospholipid antibodies in women referred for in vitro fertilization. Ann N Y Acad Sci 2007; 1108: 457-465.
24. Hughes GRV Khamashta MA. Sero-negative antiphospholipid syndrome. Ann Rheum Dis 2003; 62: 1127.